Drug library

Octreotide (Sandostatin®) for Dogs and Cats

Octreotide (Sandostatin®) for Dogs and Cats

Overview of Octreotide for Dogs and Cats

  • Octreotide, commonly known as Sandostatin®, is used for dogs and cats to treat insulinomas and gastrinomas.
  • Octreotide is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin.
  • It is a potent inhibitor of growth hormone, glucagons, and insulin; and suppresses TSH secretion and the LH response to GnRH.
  • Other physiological effects include: reduction of splanchnic blood flow, inhibition of release of serotonin, gastrin, vasoactive intestinal polypeptide, secretin, motilin, and pancreatic polypeptide.
  • After subcutaneous administration of the plain injectable form of octreotide, octreotide is quickly and completely absorbed from the injection site. Octreotide's terminal elimination half-life is 1.7 hours in humans, though the duration of action of a single dose can be up to 12 hours. About 32% of a dose is eliminated unchanged in the urine.
  • Octreotide is a prescription drug and can only be obtained from a veterinarian or by prescription from a veterinarian.
  • Octreotide is not approved for use in animals by the Food and Drug Administration (FDA) but may be legally prescribed by veterinarians as an extra-label drug.
  • Brand Names and Other Names of Octreotide

  • This drug is registered for use in humans only.
  • Human formulations: Sandostatin®, (Novartis), Sandostatin LAR® Depot (Novartis)
  • Veterinary formulations: None
  • Uses of Octreotide for Dogs and Cats

  • Treatment of insulinomas (results in dogs are equivocal)
  • Treatment of gastrinomas
  • Osteosarcoma (inconclusive results so far)
  • Acromegaly
  • Precautions and Side Effects

  • While generally safe and effective when prescribed by a veterinarian, octreotide can cause side effects in some animals.
  • Octreotide should not be used in animals with known hypersensitivity or allergy to the drug.
  • This drug should not be used in pregnant animals.
  • It may effect dietary fat absorption and depress vitamin B12 levels. B12 levels should be monitored during prolonged therapy. Can cause decreased appetite in some pets.
  • Drug Interactions

  • When mixed with TPN solutions, incompatibility may occur. A glycosyl octreotide conjugate forms when octreotide is combined with TPN solutions, decreasing its efficacy.
  • How Octreotide is Supplied


  • 0.05 mg/mL (1 mL amps)
  • 0.1 mg/mL (1 mL amps)
  • 0.2 mg/mL (5 mL multi-dose vials)
  • 0.5 mg/mL (1 mL amps)
  • 1 mg/mL (5 mL multi-dose vials)

    Depot Injection:

  • 10 mg/5 mL
  • 20 mg/5 mL
  • 30 mg/5 mL
  • Dosing Information of Octreotide for Dogs and Cats

  • Medication should never be administered without first consulting your veterinarian.
  • In dogs, the usual dose is 5 to 20 per pound (10 to 40 mg/kg) every 8 to 12 hours.
  • In cats, Octreotide has been used to treat acromegaly in cats but the results were unimpressive, possibly because the correct dose has yet to be worked out.

    ** Please note that the LAR preparation is generally only given intramuscularly. In humans, it is given once per month. There is little pertinent information about the use of LAR octreotide in dogs, cats, or ferrets.

  • Endocrine Drugs



    Gastroenterology & Digestive diseases
    Orthopedics & Musculo-Skeletal diseases
    Endocrinology & Metabolic diseases